Adimmune Corporation (TWSE: 4142) announced that, following years of negotiation, Adimmune and World Health Organization (WHO) have concluded the SMTA2 (Standard Material Transfer Agreement 2) under the Pandemic Influenza Preparedness (PIP) Framework. The SMTA2 ensures that, in the event of an influenza pandemic, the partner influenza vaccine manufacturers or pharmaceutical companies can access the virus strains from WHO to promptly develop the pandemic influenza vaccine or antiviral drugs in response. In exchange, Adimmune is obligated to donate and reserve a percentage of its newly developed pandemic influenza vaccines production for WHO to address the global pandemic and fulfill Adimmune’s commitments and obligations under the SMTA2.

In recent years, in response to potential influenza pandemic, WHO has engaged in negotiations and signed the SMTA2 with select global pharmaceutical companies possessing expertise in export shipping and mass production, aiming to secure vaccines in the event of an influenza pandemic. To date, WHO has concluded the SMTA2s with 14 multinational pharmaceutical companies.The conclusion of the SMTA2 between Adimmune and WHO solidifies the cooperative relationship between the two entities.

To amplify Adimmune’s global market presence, the Company has participated in the Influenza Vaccine Supply (IVS) International Task Force of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) since 2012. Adimmune is listed as a member among 19 leading international manufacturers supplying influenza vaccines worldwide, such as Sanofi and GSK. Meanwhile, Adimmune possesses the unique advantage in effectively responding to new influenza pandemic and influenza vaccine production.